Metformin Teva

Metformin, the active ingredient in Metformin Teva, is a biguanide presented as an oral tablet for oral use. It reduces hepatic glucose production and increases peripheral insulin sensitivity, and is used to manage type 2 diabetes mellitus in adults.

GNH USA supplies Metformin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is a biguanide antidiabetic that improves glucose control in several metabolic conditions.

Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose. Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes. Polycystic ovary syndrome: reduces insulin resistance and may restore ovulatory function.

Metformin is generally well tolerated, but a range of adverse reactions can occur.

Common Side Effects: - Nausea - Diarrhoea - Abdominal discomfort - Metallic taste - Loss of appetite - Flatulence

Serious or Rare Side Effects: - Lactic acidosis (potentially life‑threatening) - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic failure - Hypoglycaemia when combined with other antidiabetics - Vitamin B12 deficiency with long‑term use - Acute pancreatitis (rare)

Metformin should be used with attention to several safety considerations. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: avoid in patients with significant liver disease due to lactic acidosis risk. - Lactic acidosis: discontinue promptly if symptoms such as unexplained fatigue, dyspnoea, or abdominal pain develop. - Vitamin B12 monitoring: consider periodic assessment during long‑term therapy. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast media: increase risk of lactic acidosis; suspend metformin before and after imaging. - Alcohol: potentiates lactic acidosis. - Cimetidine: may raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors and ARBs: may affect renal function, requiring dose adjustment. - Beta‑blockers: can mask hypoglycaemia symptoms. - Diuretics: may reduce renal clearance of metformin. - Corticosteroids: may increase blood glucose, necessitating tighter monitoring. - Warfarin: may alter INR, requiring regular coagulation checks.